NCT03847376Approved For Marketing不适用
Rilpivirine Long Acting Single Patient Requests
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
研究概览
简要总结
The main purpose of this pre-approval access program (PAAP) is to provide rilpivirine Long Acting (RPV LA) injectable suspension for the treatment of human immunodeficiency virus (HIV)-1 infection as single patient request to individuals who have no available treatment alternatives and/or limited treatment options (for example, who are unable to participate in the Phase III clinical studies or do not qualify). RPV LA can only be provided if participants are also eligible for cabotegravir Long Acting injections.
研究设计
- 研究类型
- Expanded Access
入排标准
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
Approved For Marketing
不适用
Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)Metastatic Castration-resistant Prostate CancerNCT05401214Janssen Research & Development, LLC
No Longer Available
不适用
Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A InfectionH7N9 Subtype of Influenza A VirusNCT03834376Janssen Research & Development, LLC
Unknown
不适用
Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)Depressive Disorder, Treatment-ResistantNCT03829579Janssen Research & Development, LLC
No Longer Available
不适用
Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Adult and Pediatric ParticipantsRespiratory Syncytial VirusNCT04221412Janssen Sciences Ireland UC
Unknown
不适用
Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Multiple MyelomaNCT05503550Janssen Research & Development, LLC